2-Allyl-1-[6-(2-hydroxy-2-propyl)-2-pyridyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrazolo[3,4-d]pyrimidin-3(2H)-one , ≥95% , 955365-80-7

CAS NO.：955365-80-7

Empirical Formula: C27H32N8O2

Molecular Weight: 500.6

MDL number: MFCD17215200

PRODUCT Properties

• Melting point: 179-181°C
• Boiling point: 723.8±70.0 °C(Predicted)
• Density: 1.292
• storage temp.: -20°C
• solubility: Soluble in DMSO (70 mg/ml)
• form: solid
• pka: 13.27±0.29(Predicted)
• color: Yellow
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• InChIKey: BKWJAKQVGHWELA-UHFFFAOYSA-N
• SMILES: C1(NC2=CC=C(N3CCN(C)CC3)C=C2)=NC=C2C(=O)N(CC=C)N(C3=NC(C(O)(C)C)=CC=C3)C2=N1

Description and Uses

MK-1775 is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. MK-1775 is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

MK 1775 is used in biological studies for the abrogation of G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P280-P305+P351+P338